Skip to main content
Premium Trial:

Request an Annual Quote

RPRD Diagnostics, Orient Bio Ink PGx Deal for South Korea

NEW YORK (360Dx) – RPRD Diagnostics today announced it and Orient Bio have inked a memorandum of understanding that will expand the availability of RPRD's pharmacogenomic testing services to South Korea.

Additionally, Orient Bio will diversify its business to include new areas, including precision medicine and clinical PGx, said RPRD, which stands for Right Patient Right Drug.

Financial and other terms of the deal were not disclosed.

RPRD was spun out of the Medical College of Wisconsin last year and offers tests to help physicians decide which drugs are the most appropriate for their patients. RPRD Founder and CEO Ulrich Broeckel noted in a statement today that of particular interest to Orient Bio is his firm's recently launched CNT Panel "which is highly relevant for patients of East Asian ethnicity who may receive thiopurine drug treatment, prescribed for patients with leukemia, in addition to other diseases."